Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy

European Urology

Volumn 65, Issue 6, 2014, Pages 1171-1177

  Punnen, Sanoj ^a   Freedland, Stephen J ^b,c   Presti Jr , Joseph C ^d,e   Aronson, William J ^f,g   Terris, Martha K ^h,i   Kane, Christopher J ^j   Amling, Christopher L ^k   Carroll, Peter R ^a   Cooperberg, Matthew R ^a,l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ MEDICAL COLLEGE OF GEORGIA   (United States)

^j Rady Children's Specialists of San Diego   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Nomogram; Outcomes; Prostate cancer; Radical prostatectomy

Indexed keywords

ADULT; ARTICLE; CANCER MORTALITY; CANCER OF THE PROSTATE RISK ASSESSMENT POSTSURGICAL SCORE; CANCER RECURRENCE; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TREATMENT OUTCOME; AGED; BLOOD; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROBABILITY; PROCEDURES; PROSTATE TUMOR; RISK ASSESSMENT; VALIDATION STUDY;

PROSTATE SPECIFIC ANTIGEN;

AGED; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NOMOGRAMS; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84899520647     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.058     Document Type: Article

References (26)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 Ca Cancer J Clin 63 2013 11 30
2. I.M. Thompson Jr., C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial JAMA 296 2006 2329 2335
3. S.F. Shariat, P.I. Karakiewicz, C.G. Roehrborn, and M.W. Kattan An updated catalog of prostate cancer predictive tools Cancer 113 2008 3075 3099
4. L. Budäus, H. Isbarn, and P. Tennstedt et al. Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients BJU Int 110 2012 1714 1720
5. M.R. Cooperberg, S.J. Freedland, and D.J. Pasta et al. Multiinstitutional validation of the UCSF Cancer of the Prostate Risk Assessment for prediction of recurrence after radical prostatectomy Cancer 107 2006 2384 2391
6. M.R. Cooperberg, J.F. Hilton, and P.R. Carroll The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy Cancer 117 2011 5039 5046
7. F. Ishizaki, M.A. Hoque, and T. Nishiyama et al. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy Jpn J Clin Oncol 41 2011 1259 1264
8. S. Loeb, G.F. Carvalhal, D. Kan, A. Desai, and W.J. Catalona External validation of the Cancer of the Prostate Risk Assessment (CAPRA) score in a single-surgeon radical prostatectomy series Urol Oncol 30 2012 584 589
9. G. Lughezzani, L. Budäus, and H. Isbarn et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy Eur Urol 57 2010 562 568
10. M. May, N. Knoll, and M. Siegsmund et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy: results from a European multicenter survey of 1,296 patients J Urol 178 2007 1957 1962 discussion 1962
11. K.H. Zhao, D.J. Hernandez, M. Han, E.B. Humphreys, L.A. Mangold, and A.W. Partin External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score Urology 72 2008 396 400
12. F.R. Schroeck, W.J. Aronson, and J.C. Presti Jr. et al. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int 103 2009 603 608
13. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis J Natl Cancer Inst 101 2009 878 887
14. M.S. Cohen, R.S. Hanley, and T. Kurteva et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis Eur Urol 54 2008 371 381
15. N.M. Corcoran, M.K. Hong, and R.G. Casey et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence BJU Int 108 2011 E202 E210
16. B.M. Whitley, D.M. Moreira, and J.A. Thomas et al. Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database Prostate Cancer Prostatic Dis 14 2011 361 366
17. A.J. Stephenson, P.T. Scardino, and J.A. Eastham et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 2005 7005 7012
18. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
19. A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565 574
20. D.F. Penson, and J.M. Chan Prostate cancer J Urol 177 2007 2020 2029
21. S.A. Boorjian, R.H. Thompson, and M.K. Tollefson et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893 899
22. S.J. Freedland, E.B. Humphreys, and L.A. Mangold et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439
23. E.M. Messing, J. Manola, and J. Yao et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479
24. I.M. Thompson, C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
25. A.J. Stephenson, P.T. Scardino, and M.W. Kattan et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035 2041
26. M.W. Kattan, and T.A. Gerds Making and evaluating a statistical prediction model for the absolute risk of prostate cancer recurrence Cancer 117 2011 5026 5028